Amgen Inc. Overview
Pro stress-test →Amgen is a multinational biopharmaceutical company founded in 1980 and headquartered in Thousand Oaks, California, employing around 28,000 people. The company emphasizes research-driven innovation to address unmet medical needs globally, with a focus on oncology, inflammation, cardiovascular disease, and bone health. Amgen delivered strong performance in 2025, with double-digit growth in revenues and earnings per share, with full-year total revenues increasing 10% to $36.8 billion.
Strategic Profile
Pro stress-test →Amgen enters 2026 with momentum across a broad portfolio of medicines and a clear path towards advancing innovative therapies to deliver sustained long-term growth. The company has launched an $86 billion capital return program, highlighting its long-term commitment to shareholder value and reinforcing its position in the global biotech market. Key growth drivers include blockbuster drugs like Repatha (cardiovascular), EVENITY (bone health), and TEZSPIRE (respiratory), alongside late-stage obesity pipeline candidates like MariTide.
Competitive Landscape
Pro stress-test →Amgen competes in the large-cap biopharmaceutical space alongside Roche, Pfizer, Merck, Eli Lilly, and AstraZeneca. The company maintains competitive advantages through blockbuster franchises in cardiovascular, oncology, inflammation, and bone health. However, biosimilar competition intensifies for established drugs like Prolia, XGEVA, and Enbrel, requiring continuous innovation through pipeline advancement including obesity therapeutics (MariTide) and emerging oncology assets.
Industry Context
Amgen Inc. operates in Biopharmaceuticals - Large-cap biologics, specialty pharmaceuticals, and oncology.
Key facts
Founded: 1980 · Headquarters: Thousand Oaks, California · Employees: 28,000 · Revenue: $36.8B · Market cap: $180B+